Skip to main content

Advertisement

SpringerLink
Log in

Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts

An immunohistochemical study

  • Article
  • Published:
Pathology & Oncology Research

Abstract

Xenografted human pancreatic tumors (5 ductal adenocarcinomas, 1 leiomyosarcoma, altogether 26 samples) were investigated about their immunohistochemical expression of epidermal growth factor receptor (EGFR), somatostatin (SS) and bcl-2 protein. The expression of the EGFR varied from tumor to tumor. One originally negative carcinoma became immunoreactive during passagings, one tumor has lost its early positive expression, and in 3 cancer lines a phenotypically constant pattern was seen. SS immunoreactivity was practically absent in all tumor samples. Concerning bcl-2 expression, different staining patterns were observed among the carcinomas, but the leiomyosarcoma has retained its strong positivity during xenograftings. In the PZX-5 carcinoma line that was originally negative, the one-month Sandostatin treatment induced the strong expression of bcl-2 protein suggesting a development of an acquired resistance against programmed cell death in this tumor.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

EGFR:

epidermal growth factor receptor

SS:

somatostatin

PBS:

phosphate buffered saline

DAB:

3,3′ diaminobenzidine

BOP:

N-Nitrosobis(2-oxopropyl)amine

References

  1. Bell K, Bronner MP, Pasha T, et al: Expression of proliferating cell nuclear antigen in gastrointestinal tract lesions and its relationship to bcl-2 expression. Pathobiology 64:91–98, 1996.

    Article  PubMed  CAS  Google Scholar 

  2. Berchem GJ, Bosseler M, Sugars LY, et al: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 55:735–738, 1995.

    PubMed  CAS  Google Scholar 

  3. Bocsi J, Zalatnai A: Establishment and long term xenografting of human pancreatic carcinomas in immunosuppressed mice: Changes and stability in morphology, DNA ploidy and proliferative activity. J Cancer Res Clin Oncol 125:9–19, 1999.

    Article  PubMed  CAS  Google Scholar 

  4. Chester JF, Gaissert HA, Ross JS, et al: Pancreatic cancer in the Syrian golden hamster induced by N-Nitrosobis(2-oxopropyl) amine: cocarcinogenic effect of epidermal growth factor. Cancer Res 46:2954–2957, 1986.

    PubMed  CAS  Google Scholar 

  5. Fisher WE, Doran TA, Muscarella II P, et al: Expression of somatostatin receptor subtype 1–5 genes in human pancreatic cancer. J Natl Cancer Inst 90:322–324, 1998.

    Article  PubMed  CAS  Google Scholar 

  6. Gansauge F, Gansauge S, Schmidt E, et al: Prognostic significance of molecular alterations in human pancreatic carcinoma — an immunohistochemical study. Langenbecks Arch Surg 383:152–155, 1998.

    PubMed  CAS  Google Scholar 

  7. Gower WR jr, Risch RM, Godellas CV, et al: HPAC, a new human glucocorticoid-sensitive pancreatic ductal adenocarcinoma cell line. In Vitro Cell Developm Biol Anim 30A:151–161, 1994.

    Article  CAS  Google Scholar 

  8. Hockenbery DM, Zutter M, Hickey W, et al: BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 88:6961–6966, 1991.

    Article  PubMed  CAS  Google Scholar 

  9. Kuwashima Y, Kobayashi Y, Kurosumi M, et al: Inverse correlation between bcl-2 expression and cell growth fraction in human endometrial adenocarcinoma tissue. Anticancer Res 17:3773–3776, 1997.

    PubMed  CAS  Google Scholar 

  10. Lemoine NR, Hughes CM, Barton CM, et al: The epidermal growth factor receptor in human pancreatic cancer. J Pathol 166:7–12, 1992.

    Article  PubMed  CAS  Google Scholar 

  11. Mäkinen K, Hakala T, Lipponen P, et al: Clinical contribution of bcl-2, p53 and Ki-67 proteins in pancreatic ductal adenocarcinoma. Anticancer Res 18:615–618, 1998.

    PubMed  Google Scholar 

  12. Matsuo H, Maruo T, Samoto T: Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82:293–299, 1997.

    Article  PubMed  CAS  Google Scholar 

  13. Mejia MC, Navarro S, Pellin A, et al: Study of bcl-2 protein expression and the apoptosis phenomenon in neuroblastoma. Anticancer Res 18:801–806, 1998.

    PubMed  CAS  Google Scholar 

  14. Nakanishi H, Ohsawa M, Naka N, et al: Immunohistochemical detection of bcl-2 and p53 proteins and apoptosis in soft tissue sarcoma: their correlations with prognosis. Oncology 54:238–244, 1997.

    Article  PubMed  CAS  Google Scholar 

  15. Ohshio G, Suwa H, Imamura T, et al: An immunohistochemical study of bcl-2 and p53 protein expression in pancreatic carcinomas. Scand J Gastroenterol 33:535–539, 1998.

    Article  PubMed  CAS  Google Scholar 

  16. Poston GJ, Townsend CM jr, Rajareman S: Effect of somatostatin and tamoxifen on the growth of human pancreatic cancers in nude mice. Pancreas 5:151–157, 1990.

    Article  PubMed  CAS  Google Scholar 

  17. Qin Y, Ertl T, Groot K, et al: Somatostatin analog RC-160 inhibits growth of CFPAC-1 human pancreatic cancer cells in vitro and intracellular proliferation of cyclic adenosine monophosphate. Int J Cancer 60:694–700, 1995.

    Article  PubMed  CAS  Google Scholar 

  18. Redding TW, Schally AV: Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc Natl Acad Sci USA 81:248–252, 1984.

    Article  PubMed  CAS  Google Scholar 

  19. Reed JC: Bcl-2 family proteins and their hormonal control of cell life and death in normalcy and neoplasia. Vitamins and Hormones 53:99–138, 1997.

    Article  PubMed  CAS  Google Scholar 

  20. Robertson JF, Watson SA, Hardcastle JD: Effect of gastrointestinal hormones and synthetic analogues on the growth of pancreatic cancer. Int J Cancer 63:69–75, 1995.

    Article  PubMed  CAS  Google Scholar 

  21. Rosenberg L, Barkun AN, Denis MH, et al: Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Cancer 75:23–28, 1995.

    Article  PubMed  CAS  Google Scholar 

  22. Saegusa M, Okayasu I: Bcl-2 is closely correlated with favorable prognostic factors and inversely associated with p53 protein accumulation in endometrial carcinomas: immunohistochemical and polymerase chain reaction/loss of heterozygosity findings. J Cancer Res Clin Oncol 123:429–434, 1997.

    Article  PubMed  CAS  Google Scholar 

  23. Sinicrope FA, Evans DB, Leach SD, et al: Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin Cancer Res 2:2015–2022, 1996.

    PubMed  CAS  Google Scholar 

  24. Stefanaki K, Rontogiannis D, Vamvouka C, et al: Immunohistochemical detection of bcl-2, p53, mdm2 and p21/waf 1 proteins in small-cell lung carcinomas. Anticancer Res. 18:1167–1173, 1998.

    PubMed  CAS  Google Scholar 

  25. Szende B, Zalatnai A, andSchally AV: Programmed cell death (apoptosis) in pancreatic cancers of hamsters after treatment with analogs of both luteinizing hormone-releasing hormone and somatostatin. Proc Natl Acad Sci USA 86:1643–1647, 1989.

    Article  PubMed  CAS  Google Scholar 

  26. Takeda Y, Escribano MJ: Effects of insulin and somatostatin on the growth and the colony formation of two human pancreatic cancer cell lines. J Cancer Res Clin Oncol 117:416–420, 1991.

    Article  PubMed  CAS  Google Scholar 

  27. Teixeira C, Reed JC, Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl-2 protooncogene expression in human breast cancer cells. Cancer Res 55:3902–3907, 1995.

    PubMed  CAS  Google Scholar 

  28. Uegaki K, Nio Y, Inoue Y, et al: Clinicopathological significance of epidermal growth factor and its receptor in human pancreatic cancer. Anticancer Res 17:3841–3847, 1997.

    PubMed  CAS  Google Scholar 

  29. Upp JR, Olson D, Poston GJ, et al: Inhibition of growth of two human pancreatic adenocarcinomas in vivo by somatostatin analog SMS 201–995. Am J Surg 155:29–35, 1983.

    Google Scholar 

  30. Vidal C, Rauly I, Zeggari M, et al: Up-regulation of somatostatin receptors by epidermal growth factor and gastrin in pancreatic cancer cells. Mol Pharmacol 46:97–104, 1994.

    PubMed  CAS  Google Scholar 

  31. Vinter-Jensen L, Juhl CO, Teglbjaerg PS, et al: Systemic treatment with epidermal growth factor in pigs induces ductal proliferations in the pancreas. Gastroenterology 113:1367–1374, 1997.

    Article  PubMed  CAS  Google Scholar 

  32. Wada M, Doi R, Hosotani R, et al: Expression of bcl-2 and PCNA in duct cells after pancreatic duct ligation in rats. Pancreas 15:176–182, 1997.

    Article  PubMed  CAS  Google Scholar 

  33. Wada M, Hosotani R, Lee JU, et al: An exogenous cdk inhibitor, butyrolactone-1, induces apoptosis with increased Bax/Bcl-2 ratio in p53-mutated pancreatic cancer cells. Anticancer Res 18:2559–2566, 1998.

    PubMed  CAS  Google Scholar 

  34. Wang DG, Johnston CF, Buchanan KD: Oncogene expression in gastroenteropancreatic neuroendocrine tumors: implications for pathogenesis. Cancer 80:668–675, 1997.

    Article  PubMed  CAS  Google Scholar 

  35. Weckbecker G, Tolcsvai L, Liu R, et al: Preclinical studies on the anticancer activity of somatostatin analogue octreotide (SMS 201–995). Metabolism 41: Suppl. 2., 99–103, 1992.

    Article  PubMed  CAS  Google Scholar 

  36. Witty JP, Jensen RA andJohnson AL: Expression and localization of Bcl-2 related proteins in human ovarian cancers. Anticancer Res 18:1223–1230, 1998.

    PubMed  CAS  Google Scholar 

  37. Yan JJ, Chen FF, Tsai YC, Jin YT: Immunohistochemical detection of bcl-2 protein in small cell carcinomas. Oncology 53:6–11, 1996.

    PubMed  CAS  Google Scholar 

  38. Zalatnai A, Bocsi J, Timár F, et al: Establishment and characterization of a new transplantable pancreatic cancer xenograft (PZX-5) in immunosuppressed mice. Internatl J Pancreatol 23:51–62, 1998.

    CAS  Google Scholar 

  39. Zalatnai A, Kovács M, Flautner L, et al: Pancreatic leiomyosarcoma. Case report with immunohistochemical and flow cytometric studies. Virchows Arch 432:469–472, 1998.

    Article  PubMed  CAS  Google Scholar 

  40. Zalatnai A, Schally AV: Treatment of the N-Nitrosobis/2-oxo-propyl/amine-induced pancreatic cancer in Syrian golden hamsters with D-Trp-6-LH-RH and somatostatin analog RC-160 microcapsules. Cancer Res 49:1810–1815, 1989.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Institute of Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Üllői út 26., H-1085, Budapest, Hungary

    Attila Zalatnai M.D., Ph.D.

Authors
  1. Attila Zalatnai M.D., Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Attila Zalatnai M.D., Ph.D..

Additional information

This work was supported by the Hungarian Scientific Research Fund (OTKA T 23697) and by the Hungarian Cancer Foundation

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zalatnai, A. Epidermal growth factor receptor, somatostatin and Bcl-2 in human pancreatic tumor xenografts. Pathol. Oncol. Res. 5, 146–151 (1999). https://doi.org/10.1053/paor.1999.0176

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1053/paor.1999.0176

Keywords

Search

Navigation